Robert M. Prins

16.6k total citations · 2 hit papers
140 papers, 8.7k citations indexed

About

Robert M. Prins is a scholar working on Immunology, Oncology and Genetics. According to data from OpenAlex, Robert M. Prins has authored 140 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Immunology, 62 papers in Oncology and 42 papers in Genetics. Recurrent topics in Robert M. Prins's work include Immunotherapy and Immune Responses (60 papers), Glioma Diagnosis and Treatment (41 papers) and Cancer Immunotherapy and Biomarkers (34 papers). Robert M. Prins is often cited by papers focused on Immunotherapy and Immune Responses (60 papers), Glioma Diagnosis and Treatment (41 papers) and Cancer Immunotherapy and Biomarkers (34 papers). Robert M. Prins collaborates with scholars based in United States, Switzerland and Germany. Robert M. Prins's co-authors include Linda M. Liau, Valeria R. Fantin, Marie C. Keenan, Joshua D. Rabinowitz, Shengfang Jin, David W. White, Matthew G. Vander Heiden, Katharine Yen, Edward M. Driggers and Lewis C. Cantley and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Robert M. Prins

129 papers receiving 8.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

2009 3.1k citations Robert M. Prins, Linda M. Liau et al. profile →
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

2015 471 citations Hideho Okada, Michael Weller et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert M. Prins United States	38	3.5k	3.1k	3.0k	3.0k	2.2k	140	8.7k
Jason T. Huse United States	50	6.2k 1.8×	2.8k 0.9×	4.8k 1.6×	2.9k 1.0×	3.6k 1.6×	131	12.3k
Linda M. Liau United States	54	6.0k 1.7×	2.7k 0.9×	5.8k 1.9×	3.2k 1.1×	4.0k 1.8×	221	13.7k
Russell O. Pieper United States	44	3.9k 1.1×	1.2k 0.4×	1.9k 0.6×	2.1k 0.7×	1.7k 0.8×	105	6.7k
Frank B. Furnari United States	52	7.9k 2.3×	1.2k 0.4×	3.0k 1.0×	3.1k 1.0×	3.0k 1.4×	127	12.0k
Annick Desjardins United States	51	3.2k 0.9×	1.4k 0.4×	6.3k 2.1×	2.6k 0.9×	2.2k 1.0×	247	10.0k
Katrin Lamszus Germany	53	3.8k 1.1×	1.0k 0.3×	2.5k 0.8×	2.2k 0.7×	2.1k 1.0×	154	7.8k
Hideho Okada United States	54	2.8k 0.8×	5.1k 1.6×	2.6k 0.9×	4.1k 1.4×	1.1k 0.5×	198	8.8k
Albert J. Wong United States	54	6.3k 1.8×	1.3k 0.4×	1.9k 0.6×	3.8k 1.3×	1.3k 0.6×	94	10.5k
Christel Herold‐Mende Germany	63	6.3k 1.8×	2.0k 0.6×	5.6k 1.9×	4.3k 1.4×	3.6k 1.6×	313	14.4k
Rolf Bjerkvig Norway	59	6.3k 1.8×	1.2k 0.4×	3.8k 1.2×	3.4k 1.1×	3.3k 1.5×	235	12.7k

Countries citing papers authored by Robert M. Prins

Since Specialization

Citations

This map shows the geographic impact of Robert M. Prins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert M. Prins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert M. Prins more than expected).

Fields of papers citing papers by Robert M. Prins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert M. Prins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert M. Prins. The network helps show where Robert M. Prins may publish in the future.

Co-authorship network of co-authors of Robert M. Prins

This figure shows the co-authorship network connecting the top 25 collaborators of Robert M. Prins. A scholar is included among the top collaborators of Robert M. Prins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert M. Prins. Robert M. Prins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhu, Yichen, Zhe Li, Aiqi Zhao, et al.. (2025). Allogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safety. Molecular Therapy. 33(12). 6041–6062. 3 indexed citations

Hou, Andrew J., Benjamin R. Uy, Begonya Comin-Anduix, et al.. (2024). IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma. Neuro-Oncology. 26(10). 1850–1866. 32 indexed citations

Sun, Lu, Yanjun Zhang, Robert M. Prins, et al.. (2023). Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors. Frontiers in Immunology. 14. 1176994–1176994. 18 indexed citations

Wirsching, Hans‐Georg, Jörg Felsberg, Michael Prummer, et al.. (2023). Spatial immune profiling of glioblastoma identifies an inflammatory, perivascular phenotype associated with longer survival. Acta Neuropathologica. 146(4). 647–649. 3 indexed citations

Hu, Junhui, Ping Tan, Nicholas Bayley, et al.. (2023). Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma. Signal Transduction and Targeted Therapy. 8(1). 155–155. 40 indexed citations

Hwang, Eugene, Elias Sayour, Catherine Flores, et al.. (2022). The current landscape of immunotherapy for pediatric brain tumors. Nature Cancer. 3(1). 11–24. 34 indexed citations

Lee, Alex, Lu Sun, Aaron Mochizuki, et al.. (2021). Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nature Communications. 12(1). 6938–6938. 135 indexed citations

Subbiah, Vivek, Ravi Murthy, David S. Hong, et al.. (2018). Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. Clinical Cancer Research. 24(16). 3845–3856. 29 indexed citations

Mochizuki, Aaron, Isaura M. Frost, Ashley Plant, et al.. (2017). Precision Medicine in Pediatric Neurooncology: A Review. ACS Chemical Neuroscience. 9(1). 11–28. 15 indexed citations

10.

Sedighim, Shaina, Tina Wang, Joseph Antonios, et al.. (2016). TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination. Cancer Immunology Research. 4(5). 412–418. 53 indexed citations

11.

Li, Sichen, Reshmi Chowdhury, Fei Liu, et al.. (2014). Tumor-Suppressive miR148a Is Silenced by CpG Island Hypermethylation in IDH1 -Mutant Gliomas. Clinical Cancer Research. 20(22). 5808–5822. 29 indexed citations

12.

Fong, Brendan, Richard C. Jin, Xiaoyan Wang, et al.. (2012). Correction: Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients. PLoS ONE. 7(4). 5 indexed citations

13.

Prins, Robert M., Horacio Soto, Vera Konkankit, et al.. (2010). Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy. Clinical Cancer Research. 17(6). 1603–1615. 334 indexed citations

14.

Vo, Dan D., Robert M. Prins, Jonathan L. Begley, et al.. (2009). Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824. Cancer Research. 69(22). 8693–8699. 119 indexed citations

15.

Prins, Robert M., Noah Craft, Kevin W. Bruhn, et al.. (2006). The TLR-7 Agonist, Imiquimod, Enhances Dendritic Cell Survival and Promotes Tumor Antigen-Specific T Cell Priming: Relation to Central Nervous System Antitumor Immunity. The Journal of Immunology. 176(1). 157–164. 160 indexed citations

16.

Prins, Robert M., Dan D. Vo, Haumith Khan-Farooqi, et al.. (2006). NK and CD4 Cells Collaborate to Protect against Melanoma Tumor Formation in the Brain. The Journal of Immunology. 177(12). 8448–8455. 52 indexed citations

17.

Craft, Noah, Kevin W. Bruhn, Bidong D. Nguyen, et al.. (2005). The TLR7 Agonist Imiquimod Enhances the Anti-Melanoma Effects of a Recombinant Listeria monocytogenes Vaccine. The Journal of Immunology. 175(3). 1983–1990. 74 indexed citations

18.

Prins, Robert M., Francesca Incardona, Paul P. Lee, et al.. (2004). Characterization of Defective CD4−CD8− T Cells in Murine Tumors Generated Independent of Antigen Specificity. The Journal of Immunology. 172(3). 1602–1611. 30 indexed citations

19.

Prins, Robert M.. (1996). Developing business objects : a framework driven approach. McGraw-Hill eBooks. 6 indexed citations

20.

Prins, Robert M., et al.. (1991). Catalogue of systems for the monitoring of working conditions relating to health and safety. OpenGrey (Institut de l'Information Scientifique et Technique). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact